UNSPSC 51172170: Drotaverine hydrochloride

This classification denotes an antispasmotic agent with the molecular formula C24H31NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24ZVH4C669, chemically known as 1-benzyl-3,4,6,7-tetraethoxy-1,2,3,4-tetrahydroisoquinoline but more generally known as drotaverine hydrochloride, which bears US NIH Compound Identifier 1712095. European Medicines Agency schedules Drotaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01843MIG.

Most nations, for tariff and trade purposes, schedule drotaverine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, DROTAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Drotaverine hydrochloride bears US NLM NCI C97980. SMILES: CCOC1CCC(CC1OCC)/C=C\2/C3CC(C(CC3CCN2)OCC)OCC.CL.

UNSPSC 51172170 Drotaverine hydrochloride is a Commodity code nominally identifying a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code does not align with the pharmaceutical scope. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services—posted September 25, 2026 with proposals due July 23, 2026—involves laboratory testing methodologies (immunoassay screening with LC/MS/MS or GC/MS confirmation, oral fluid and hair testing) and staffing of two collection sites rather than procurement of drotaverine hydrochloride itself. The code shows little recent activity directly relevant to pharmaceutical procurement; the single posted opportunity appears to be tagged to this code without substantive connection to its nominal product scope.

The opportunity is county-level and Texas-based, issued by Collin County Community Supervision and Corrections Department under an RFP with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, with three optional one-year renewal periods. The county requires SAMHSA, TX DPS, or CAP lab certification and pricing on a per-test basis across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives). Evaluation emphasizes vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews worth up to 30 points. Annual testing demand is approximately 25,031 tests. The anticipated award date is August 10, 2026.